Premium
PPARγ activation mitigates glucocorticoid receptor‐induced excessive lipolysis in adipocytes via homeostatic crosstalk
Author(s) -
Hasan Arif U.,
Ohmori Koji,
Hashimoto Takeshi,
Kamitori Kazuyo,
Yamaguchi Fuminori,
Rahman Asadur,
Tokuda Masaaki,
Kobori Hiroyuki
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26631
Subject(s) - adipose triglyceride lipase , lipolysis , downregulation and upregulation , endocrinology , medicine , perilipin , lipogenesis , chemistry , adipose tissue , lipid metabolism , glucocorticoid receptor , glucose homeostasis , glucocorticoid , insulin resistance , insulin , biology , biochemistry , gene
Proper balance between lipolysis and lipogenesis in adipocytes determines the release of free fatty acids (FFA) and glycerol, which is crucial for whole body lipid homeostasis. Although, dysregulation of lipid homeostasis contributes to various metabolic complications such as insulin resistance, the regulatory mechanism remains elusive. This study clarified the individual and combined roles for glucocorticoid receptor (GCR) and peroxisome proliferator‐activated receptor (PPAR)γ pathways in lipid metabolism of adipocytes. In mature 3T3‐L1 adipocytes, GCR activation using dexamethasone upregulated adipose triglyceride lipase (ATGL) and downregulated phosphoenolpyruvate carboxykinase (PEPCK), resulting in enhanced glycerol release into the medium. In contrast, PPARγ ligand pioglitazone modestly upregulated ATGL and hormone sensitive lipase (HSL), but markedly enhanced PEPCK and glycerol kinase (GK), thereby suppressed glycerol release. Dexamethasone showed permissive like effect on PPARγ target genes including perilipin A and aP2, therefore co‐administration of dexamethasone and pioglitazone demonstrated synergistic upregulation of these enzymes excepting PEPCK, of which downregulation by dexamethasone was abolished by pioglitazone to the level above control. Thus, the excessive glycerol release was prevented as the net outcome of the co‐administration. Consistently, the bodipy stain demonstrated that dexamethasone reduced the amount of cytosolic lipid, which was preserved in co‐treated adipocytes. Moreover, silencing of PPARγ suppressed the synergistic effects of co‐treatment on the lipolytic and lipogenic genes, and therefore the GCR pathway indeed involves PPARγ. In conclusion, crosstalk between GCR and PPARγ is largely synergistic but counter‐regulatory in lipogenic genes, of which enhancement prevents excessive glycerol and possibly FFA release by glucocorticoids into the circulation.